About: Translation: Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical COVID-19: National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Translation: Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical COVID-19: National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Translation: Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical COVID-19: National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
Creator	Program, Development Research, Funding：national Key
source	PMC
abstract	The prevention and treatment of COVID-19 nationwide has entered a tackling phase. Effective treatment of severe and critically ill patients is the key to reducing the fatality of the disease. The artificial liver blood purification system can remove inflammatory factors, alleviate the damage of the inflammatory response to the body, and has important value for the treatment of severe COVID-19. Led by Academician Lanjuan Li, based on the experience of treating patients across the country, integrating the opinions of experts from all over the country, the center summarized and formulated the consensus including the basic principles, treatment indications, relative contraindications, mode selection, monitoring indicators, and efficacy evaluation of artificial liver, which provides reference for treatment of severe COVID-19 patients.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1097/im9.0000000000000021
has license	cc-by-nc-nd
sha1sum (hex)	ea5ffd611f18088e13bd2e0e9d10b61bc3de8058
schema:url	https://doi.org/10.1097/im9.0000000000000021
resource representing a document's title	Translation: Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical COVID-19: National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
has PubMed Central identifier	PMC7227200
resource representing a document's body	covid:ea5ffd611f18088e13bd2e0e9d10b61bc3de8058#body_text
is schema:about of	named entity 'experience' named entity 'critically ill' named entity 'indications' named entity 'Emergency' named entity 'BLOOD PURIFICATION' named entity 'DAMAGE' named entity 'prevention' named entity 'purification' named entity 'mode' named entity 'relative contraindications' named entity 'severe' named entity 'Academician' named entity 'inflammatory factors' named entity 'COVID-19' named entity 'Research and Development' named entity 'protamine' named entity 'plasma' named entity 'respiratory failure' named entity 'albumin' named entity 'CRP' named entity 'IL-10' named entity 'respiratory function' named entity 'continuous hemofiltration' named entity 'treatment of patients' named entity 'X-ray' named entity 'cytokine storm' named entity 'COVID-19' named entity 'IL-6' named entity 'artificial liver' named entity 'coagulation' named entity 'plasma' named entity 'adsorption' named entity 'adsorption' named entity 'fatality rate' named entity 'arterial blood gas' named entity 'coagulation' named entity 'plasma exchange' named entity 'plasma' named entity 'SARS' named entity 'liver' named entity 'hypotension' named entity 'plasma' named entity 'vital signs' named entity 'fatality rate' named entity 'COVID' named entity 'coagulation factors' named entity 'plasma' named entity 'Inflammatory cytokines' named entity 'hemodialysis' named entity 'peripheral blood lymphocyte' named entity 'H7N9' named entity '2.0' named entity 'cytokine storm' named entity 'perfusion' named entity 'oxygen' named entity 'partial pressure' named entity 'Clinical Research Center' named entity 'inflammatory factors' named entity 'COVID' named entity 'endotoxins' named entity 'avian influenza' named entity 'hypoxemia' named entity 'Hematocrit' named entity 'COVID-19' named entity 'C-reactive protein' named entity 'allergies' named entity 'PSI' named entity 'lung' named entity 'heparin' named entity 'adsorption' named entity 'COVID' named entity 'viral infection' named entity 'severe head injury' named entity 'mmol/L' named entity 'inflammation of the lungs' named entity 'artificial liver' named entity 'blood products' named entity 'PSI' named entity 'oxygen' named entity 'infectious diseases' named entity 'perfusion' named entity 'renal insufficiency' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software